NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 13 October 2022, 9:30am

**Location:** Via Zoom Conference Call

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Dr Hatim Abdulhussein Present for all 1 to 4.3.2
4. Professor Iolo Doull Present for all items
5. Professor Francis Drobniewski Present for all items
6. Dr Bushra Hasnie Present for all items
7. Professor Nicholas Latimer Present for all items
8. Dr Rhiannon Owen Present for all items
9. Anna Pracz Present for all items
10. Gabriel Rogers  Present for all items
11. Dr Toby Smith Present for all items
12. Mary Weatherstone Present for all items
13. Professor Nicky Welton Present for all items
14. Nigel Westwood Present for all items
15. Peter Wheatley-Price Present for items 1 to 4.3.2
16. Dr Stuart Williams Present for all items
17. Tony Wootton Present for all items

NICE staff present

Richard Diaz, Associate Director Items 1 to 4.3.2

Henry Edwards, Associate Director Items 1 to 4.1.3 & 5 to 6.1.3

Daniel Davies, Project Manager Items 1 to 4.3.2

Jeremy Powell, Project Manager Items 5 to 6.1.3

Catrin Austin, Heath Technology Assessment Adviser Items 1 to 4.3.2 & 6 to 6.1.3

Yelan Guo, Heath Technology Assessment Adviser Items 5 to 5.2.2

Ewa Rupniewska, Heath Technology Assessment Adviser Items 1 to 4.3.2

Carl Prescott, Heath Technology Assessment Adviser Items 6 to 6.1.3

Rufaro Kausi, Heath Technology Assessment Analyst Items 1 to 4.3.2

Stephen Norton, Heath Technology Assessment Analyst Items 1 to 4.3.2

Anna Willis, Heath Technology Assessment Analyst Items 1 to 4.3.2

Catherine Spanswick, Heath Technology Assessment Analyst Items 6 to 6.1.3

Sharlene Ting, Heath Technology Assessment Analyst Items 5 to 5.2.2

Philip Williams, Business Analyst, RIA Items 1 to 4.31 & 5 to 6.1.3

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment Items 6 to 6.1.3

Neha Jiandani, Technical Analyst, Commercial Risk Assessment Items 1 to 4.3.2

Ian Watson, Senior Methods Adviser Items 1 to 4.3.2

Katharine Cresswell, Senior Analyst Items 1 to 4.2.1

Georgina Fletcher, Media Relations Executive Items 1 to 4.3.2

David Hutchings, Pharmacy Clinical Fellow Items 6 to 6.1.3

Emilene Coventry, Senior Medical Editor Items 1 to 4.3.2

Hayley Garnett, Senior Medical Editor Items 5 to 5.2.2

Ruth Melville, Senior Medical Editior Items 6 to 6.1.5

Laura Marsden, Public Involvement Adviser, PIP Items 1 to 4.2.1

Lyn Davies, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Rumana Zaman, Administrator, TA Items 5 to 6.1.3

Ayla Hudson, Apprentice, Planning & Ops Items 1 to 4.3.2 & 6 to 6.1.3

External assessment group representatives present

Mariana Bacelar, BMJ Items 1 to 4.2.1

Charlotte Karner, BMJ Items 1 to 4.2.1

Mark Rodgers, Centre for Reviews and Dissemination – York, Items 5 to 5.1.3

Claire Rothery, Centre for Reviews and Dissemination – York, Items 5 to 5.1.3

Katherine Edwards, [Liverpool Reviews and Implementation Group (LRiG)](https://www.bing.com/ck/a?!&&p=ac921e5cfe5275ebJmltdHM9MTY2Nzg2NTYwMCZpZ3VpZD0yOTcxOTkwYi00ZDdiLTZlYWItMWFiZS04ODUyNGMyMzZmNGUmaW5zaWQ9NTIwMg&ptn=3&hsh=3&fclid=2971990b-4d7b-6eab-1abe-88524c236f4e&psq=lrig&u=a1aHR0cHM6Ly93d3cubGl2ZXJwb29sLmFjLnVrL3BvcHVsYXRpb24taGVhbHRoL3Jlc2VhcmNoL2dyb3Vwcy9saXZlcnBvb2wtcmV2aWV3cy1hbmQtaW1wbGVtZW50YXRpb24tZ3JvdXAv&ntb=1) Items 6 to 6.1.3

James Mahon, [Liverpool Reviews and Implementation Group (LRiG)](https://www.bing.com/ck/a?!&&p=ac921e5cfe5275ebJmltdHM9MTY2Nzg2NTYwMCZpZ3VpZD0yOTcxOTkwYi00ZDdiLTZlYWItMWFiZS04ODUyNGMyMzZmNGUmaW5zaWQ9NTIwMg&ptn=3&hsh=3&fclid=2971990b-4d7b-6eab-1abe-88524c236f4e&psq=lrig&u=a1aHR0cHM6Ly93d3cubGl2ZXJwb29sLmFjLnVrL3BvcHVsYXRpb24taGVhbHRoL3Jlc2VhcmNoL2dyb3Vwcy9saXZlcnBvb2wtcmV2aWV3cy1hbmQtaW1wbGVtZW50YXRpb24tZ3JvdXAv&ntb=1) Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Dr Mark Aldersley, Consultant Hepatologist and Chair British Viral Hepatitis Group, Leeds Teaching Hospitals NHS Trust, items 1 to 4.1.3

Mr Paul Desmond, Patient Expert, Head of Care at Hep B Trust, items 1 to 4.1.3

Professor Will Irving, Professor and Honorary Consultant in Virology, Queens Medical Centre, items 1 to 4.1.3

Mr Navide Shenare, Patient Expert, items 1 to 4.1.3

Dr Sanjeev Patel, Clinical Adviser, NHS England, items 1 to 4.3.2

Professor Peter Clark, Clinical Lead for Cancer Drugs Fund, NHS England, items 5 to 5.2.2

Dr Mamta Garb, Haematologist and Associate Professor, University Hospitals Leicester NHS Trust, items 5 to 5.1.3

Dr Charlotte Manisty, Clinical lead for Cardio-oncology, Barts Health NHS Trust and University College London, items 5 to 5.1.3

Ms Shelagh McKinley, Acting Director of Research and Advocacy, Myeloma UK, items 5 to 5.1.3

Mr Huw Stiley, Patient Expert, nominated by Myeloma UK, items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from committee members.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee were informed that the minutes of the committee meeting held on Thursday 15 September 2022 would be circulated post-meeting.

### Appraisal of Bulevirtide for treating chronic hepatitis D [ID3732]

* 1. Part 1 – Open session
		1. The chair welcomed the clinical, patient and NHS experts, external assessment group representatives, members of the public and company representatives from Gilead.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Mark Aldersley declared an indirect financial interest due to having received lecture fees from Gilead for non-promotional meetings relating to Hepatitis C and D. It was agreed that this declaration would not prevent Dr Aldersley from providing expert advice to the committee.
* Professor Will Irving declared indirect financial interests due to being the lead investigator on a sponsored research grant from Gilead Sciences entitled “The epidemiology of HDV infection in the UK”, having participated in an Advisory Board for Gilead Sciences on HDV infection in 2021, and being an independent referee for Gilead research fellowship schemes. It was agreed these declarations would not prevent Professor Irving from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team – Mary Weatherstone (Clinical) Peter Wheatley Price (Cost) and Nigel Westwood (Lay)
	1. Part 2a – Closed session (members of the public, company representative and clinical and patient experts were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (NHS experts were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10652>

### Appraisal of Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Jassen.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Mamta Garb declared a direct financial interest, having received speaker fees for time spent in advisory meeting for Janssen, Amgen, Novartis Takeda etc in the field of myeloma MPN and ITP. Dr Garb has also received speaker fees part in educational activities organised by pharmaceutical company including Janssen, and small research grants to support services in Leicester Hospitals in the field of MGUS and diagnostics. It was agreed that these declarations would not prevent Dr Garb from providing expert advice to the committee.
* Professor Nicholas Latimer declared a non-financial professional and personal interest, as in October 2021 he was paid to give Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. Novartis are listed as a comparator company. It was agreed that this declaration would not prevent Professor Latimer from taking part in this discussion.
* Dr Charles Crawley declared a non-financial professional and personal interest, as his professional practice includes care patients with amyloidosis. It was agreed that this declaration would not prevent Dr Crawley from taking part in this discussion.
* Peter Wheatley-Price declared a direct financial interest, as his employer – Takeda - manufacture ixazomib which is a direct competitor to daratumumab in various lines of therapy in Multiple Myeloma. There are also trials listed on clinicaltrials.gov investigating ixazomib in amyloidosis. It was agreed that this declaration would prevent Peter Wheatley-Price from taking part in this discussion.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the Chair – Dr Charles Crawley.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10656>

### Appraisal of Upadacitinib for treating moderately to severely active ulcerative colitis [ID3753]

* 1. Part 2 – Closed session
		1. The committee discussed confidential information submitted for this item.
		2. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10866>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 10 November and will start promptly at 09:30am.